ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 132 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $643,525 | -94.6% | 32,080 | -92.3% | 0.00% | -100.0% |
| Q2 2023 | $11,826,366 | +1434.0% | 419,226 | +835.3% | 0.01% | – |
| Q1 2023 | $770,973 | +2.4% | 44,824 | +19.9% | 0.00% | – |
| Q4 2022 | $753,155 | -49.4% | 37,396 | -45.5% | 0.00% | -100.0% |
| Q3 2022 | $1,487,000 | +134.9% | 68,654 | +204.7% | 0.00% | – |
| Q2 2022 | $633,000 | -58.6% | 22,528 | -32.0% | 0.00% | -100.0% |
| Q1 2022 | $1,530,000 | -48.0% | 33,152 | -5.2% | 0.00% | 0.0% |
| Q4 2021 | $2,942,000 | +30.6% | 34,986 | +3.5% | 0.00% | 0.0% |
| Q3 2021 | $2,253,000 | +89.3% | 33,803 | +51.1% | 0.00% | 0.0% |
| Q2 2021 | $1,190,000 | +27.4% | 22,365 | +3.9% | 0.00% | 0.0% |
| Q1 2021 | $934,000 | -23.1% | 21,534 | -7.9% | 0.00% | 0.0% |
| Q4 2020 | $1,214,000 | +492.2% | 23,377 | +273.7% | 0.00% | – |
| Q3 2020 | $205,000 | -18.7% | 6,255 | +19.5% | 0.00% | – |
| Q2 2020 | $252,000 | – | 5,236 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |